MEDIA RELEASE | Oncology One Appoints New Non-Executive Director


Australian biotechnology company, Oncology One, has today announced the appointment of a new Non-Executive Director, Professor Shelley Dolan, a highly regarded leader in oncology and CEO of Peter MacCallum Cancer Centre.

27 October 2021, Melbourne, Australia: Australian biotech company, Oncology One Pty Ltd, today announced it has appointed Professor Shelley Dolan as a Non-Executive Director – a valuable addition to the Board as Oncology One pursues the development of promising early-stage cancer drug discovery programs.

Oncology One Chair, Mary Harney, said: “The Board welcomes Professor Dolan, whose appointment brings to Oncology One a wealth of global oncology partnership experience. Professor Dolan has extensive expertise in navigating not only the patient-centric requirements of developing innovative cancer treatments, but essential commercial pathways to ensure this process is supported and successful. We feel very fortunate to welcome her to our leadership team.

Professor Dolan was appointed Chief Executive Officer of the Peter MacCallum Cancer Centre in September 2019 and has more than two decades’ experience of Executive and Non-executive Director roles in Australia and the UK. Professor Dolan is experienced in delivering excellence in quality and performance, developing strategy, large capital schemes and innovative research projects which all require engagement with a broad range of stakeholders including patients, regulators, Consultants and other personnel, commissioners, charities, and academic partners.

Prior to joining Peter MacCallum Cancer Centre, Professor Dolan’s experience included nine years as Chief Nurse and two as Deputy Chief Executive at The Royal Marsden Hospital NHS Foundation Trust and a further two years as Chief Nurse/Chief Operating Officer and Acting Chief Executive at Kings College Hospital NHS Foundation Trust.

Professor Dolan has experience of joint ventures and partnership development across systems including the design and leadership of the Cancer Vanguard new care model of the NHS and well-developed risk management and corporate governance skills.

Newly appointed Oncology One Non-Executive Director, Professor Shelley Dolan, said: “Every day I meet people with cancer who need our care and I am looking forward to working with Oncology One to pursue more treatment options now and in the years to come.

“Cancer affects one in two people in their lifetime and it is so important that we harness fundamental science and drug discovery translation into real-world treatments that give people better and longer lives.”

The appointment of Professor Dolan is the second new board appointment this year, with Mr Tim Murphy joining the Oncology One Board in May 2021.

Oncology One is implementing a strategy focused on building a diversified small molecule oncology pipeline and aims to help translate more of Australia’s world-class cancer research into treatments. Oncology One has a purpose-built business model to deliver targeted investment to research teams and works with them to progress important research towards the clinic.

To learn more about investment or partnership opportunities with Oncology One, visit


Click here to view or download Media Release PDF.